Cytovale said Monday that it will present new data at AACC 2022 about its 10-minute IntelliSep test for sepsis and its associated system.
The firm noted it has already submitted an application to the U.S. Food and Drug Administration for clearance of the system and test, which aims to help emergency departments rapidly and more effectively triage patients.
Emergency department physicians tasked with diagnosing sepsis, a dysregulated immune response to infection that can be life-threatening, often face a scarcity of information that could lead to over- or undertreatment.
To help address this challenge, the Cytovale system directly analyzes white blood cells using rapid techniques that look at cell structure, which may make it faster and less expensive than other approaches, the firm said.
Cytovale said that the IntelliSep test was recently named an AACC Disruptive Technology Award semifinalist and is also being featured in the Disruptive Tech area of the exhibit hall during the meeting.